Skip to content

Eye movements as a biomarker to predict the cognitive remediation treatment response in patients with stable schizophrenia

Eye movements as a biomarker to predict the cognitive remediation treatment response in patients with stable schizophrenia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062704
Enrollment
Unknown
Registered
2022-08-16
Start date
2022-08-17
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

one:Cognitive training

Sponsors

Peking University Sixth Hospital, Peking University Institute of Mental Health
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Healthy control group: 1. Age between 18-40 years old; 2. Right-handedness; 3. Years of education >= 5 years. Schizophrenia group: 1. according to DSM-5 diagnostic criteria for schizophrenia; 2. Age between 18-40 years old; 3. had >= 5 years of education; 4. were largely stable, with medication type and dose stable for >1 month and no medication adjustment planned during the study, with PANSS scores: P1 (delusions), P2 (conceptual disorganization), P3 (hallucinatory behavior), P5 (exaggeration), P6 (suspicion/persecution ) and G9 (unusual thought content) scores were less than 5; 5. Right-handedness

Exclusion criteria

Exclusion criteria: Healthy control group: 1. first-degree relatives with previous mental disorders or hereditary neurological disorders; 2. eyes with nearsightedness > 800 degrees, color weakness, color blindness, or other visual disorders; 3. pregnant or lactating women; 4. the presence of contraindications to MRI. Schizophrenia group: 1. eye nearsightedness > 800 degrees, color weakness, color blindness or other visual impairment; 2. Persons who have suffered from organic brain disease, concomitant physical severe disease, or central nervous system disease; 3. Women during pregnancy or lactation; 4. had MECT or rTMS treatment in the last 6 months; 5. Currently taking a generation of antipsychotics or clozapine.

Design outcomes

Primary

MeasureTime frame
eye movement;

Secondary

MeasureTime frame
cognitive function;Function Connection;

Countries

China

Contacts

Public ContactChuan Shi
shichuan@bjmu.edu.cn+86 10 62723737

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026